JNJ

Johnson & Johnson Completes Acquisition of Shockwave Medical

Retrieved on: 
Freitag, Mai 31, 2024
Biotechnology, Health, Pharmaceutical, Health Technology, Cardiology, Patient, Cardiovascular disease, JNJ, Abiomed, Coronary artery disease, CAD, PAD, Johnson & Johnson, Peripheral artery disease, Death, Electrophysiology, Acquisition, Shock wave, Medtech, IVL, Worldwide, Pharmaceutical industry

Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.

Key Points: 
  • Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
  • Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
  • We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.”
    Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

Retrieved on: 
Dienstag, Mai 28, 2024
Patient, JNJ, YJT, J&J, Atopic dermatitis, Therapy, Boehringer Ingelheim, Engineering, Acquisition, Centerview Partners, Morgan Stanley

HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the Company has entered into a definitive agreement whereby Johnson & Johnson1 (NYSE: JNJ) acquires Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Numab to be spun-off to Numab's shareholders. YJT comprises all assets relating to NM26, an investigational first-in-class bi-specific antibody for the treatment of atopic dermatitis (AD) set to advance into Phase 2 clinical development. Under the terms of the acquisition, J&J will pay a purchase price of $1.25 billion in cash for YJT.

Key Points: 
  • YJT comprises all assets relating to NM26, an investigational first-in-class bi-specific antibody for the treatment of atopic dermatitis (AD) set to advance into Phase 2 clinical development.
  • Under the terms of the acquisition, J&J will pay a purchase price of $1.25 billion in cash for YJT.
  • NM26 targets IL-4Rα (type I and type II receptors) and IL-31 to address the hallmarks of the pathophysiology of atopic dermatitis.
  • The antibody was discovered and engineered using Numab’s proprietary MATCH™ technology platform, which is designed to fuel a new wave of multi-specific antibody drug candidates.

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

Retrieved on: 
Dienstag, Mai 28, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, IL-31, Itch, JNJ, Patient, Scratching, Risk, Johnson & Johnson, Atopic dermatitis, Depression, Therapy, Anxiety, Skin, Inflammation, Worldwide, Suicide, Standard of care, Infection, Pharmaceutical industry

NM26, which is ready to enter Phase 2 studies, targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, in atopic dermatitis (AD).

Key Points: 
  • NM26, which is ready to enter Phase 2 studies, targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, in atopic dermatitis (AD).
  • Atopic dermatitis, the most common inflammatory skin disease3, is highly heterogeneous with different disease-driving mechanisms in distinct patient subpopulations.
  • NM26 targets IL-4Rα, which triggers Th2-mediated skin inflammation4, and IL-31, which impacts skin itch and subsequent scratching that worsen the disease5.
  • “That’s why we are committed to developing differentiated bispecifics that combine the targeting of two distinct disease-driving pathways.

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

Retrieved on: 
Donnerstag, Mai 16, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, JNJ, Johnson & Johnson, Atopic dermatitis, Skin, Disease, Asthma, TSLP, Acquisition, Allergen, Inflammation, Worldwide, Vaccine

Since AD and asthma are both heterogeneous diseases with different disease-driving pathways in distinct patient subpopulations, targeting multiple pathways offers the potential to deliver high-bar efficacy and remission.

Key Points: 
  • Since AD and asthma are both heterogeneous diseases with different disease-driving pathways in distinct patient subpopulations, targeting multiple pathways offers the potential to deliver high-bar efficacy and remission.
  • PX130 also inhibits IL-22 to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens.
  • “Atopic dermatitis is the most common inflammatory skin disease, impacting more than 100 million adults worldwide,” said David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson Innovative Medicine.
  • “Integrating Proteologix bispecific antibodies into our pipeline is an important first step in fulfilling our commitment to people living with AD,” said Candice Long, Worldwide Vice President, Immunology, Johnson & Johnson.

Kenvue Announces Pricing of Secondary Offering

Retrieved on: 
Mittwoch, Mai 15, 2024
General Health, Health, Medical Supplies, Other Health, Offering, Security (finance), BofA Securities, JNJ, Deutsche Bank, KVUE, RBC Capital Markets, J. P. Morgan, Goldman Sachs, Inc., Johnson & Johnson, Telephone, Sale, Citigroup, Form, Prospectus, Bank of America, Attention, UBS, HSBC, BNP PARIBAS, Broadridge Financial Solutions

Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced today the pricing of its previously announced secondary underwritten public offering (the “Offering”) of 182,329,550 shares of its common stock (the “Shares”) at a public offering price of $20.00 per share.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced today the pricing of its previously announced secondary underwritten public offering (the “Offering”) of 182,329,550 shares of its common stock (the “Shares”) at a public offering price of $20.00 per share.
  • The Offering is expected to close on May 17, 2024, subject to the satisfaction or waiver of customary closing conditions.
  • Kenvue is not selling any shares of common stock and will not receive any proceeds from the sale of the Shares in the Offering or from the debt-for-equity exchange (as described below).
  • Following the debt-for-equity exchange, if consummated, the Selling Shareholders intend to sell the Shares to the underwriters in the Offering.

Kenvue Announces Launch of Secondary Offering

Retrieved on: 
Montag, Mai 13, 2024
General Health, Home Goods, Health, Retail, Medical Supplies, Offering, Security (finance), BofA Securities, JNJ, Exchange, J. P. Morgan, Goldman Sachs, Johnson & Johnson, Telephone, Sale, Form, Prospectus, Bank of America, Share (finance), Attention, Broadridge Financial Solutions

Following the debt-for-equity exchange, if consummated, the Selling Shareholders intend to sell the Shares to the underwriters in the Offering.

Key Points: 
  • Following the debt-for-equity exchange, if consummated, the Selling Shareholders intend to sell the Shares to the underwriters in the Offering.
  • After the completion of the proposed Offering, Johnson & Johnson will no longer own any shares of Kenvue’s common stock.
  • Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the Offering.
  • The Offering will be made only by means of a prospectus.

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

Retrieved on: 
Donnerstag, Mai 9, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, JNJ, KSF, Johnson & Johnson

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ).
  • Under the terms of the proposed transaction, shareholders of Shockwave will receive $335.00 in cash for each share of Shockwave that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, In

Retrieved on: 
Montag, Mai 6, 2024
WTFC, JNJ, Johnson & Johnson, Brodsky, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, DecisionPoint stockholders will receive $10.22 per share in cash for each share they hold.
  • Under the terms of the definitive merger agreement, the Company’s common stockholders will receive cash consideration of $3.21 per share.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Shockwave Medical Reports First Quarter 2024 Financial Results

Retrieved on: 
Montag, Mai 6, 2024
Investment, JNJ, Johnson & Johnson, Patient, Acquisition, Cardiovascular disease, Growth

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

Key Points: 
  • SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.
  • Gross profit for the first quarter of 2024 was $190.6 million compared to $140.0 million for the first quarter of 2023.
  • Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024.
  • Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical will not be hosting the previously scheduled earnings conference call today.

Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Retrieved on: 
Mittwoch, Mai 8, 2024
Other Health, Research, General Health, Professional Services, Pharmaceutical, Other Professional Services, Public Relations, Investor Relations, Science, Biotechnology, Communications, Other Science, Health, JNJ, Johnson & Johnson, Conference, Webcast, Eastern Time Zone

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida.
  • Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and John Reed, Executive Vice President, Innovative Medicine R&D will represent the Company in a session scheduled at 2:00 pm (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240508472086/en/